Amgen (AMGN)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$367.99-0.03%
Close 2026-07-08 · 1-day change
Reading AMGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track AMGN free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading AMGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track AMGN free→Amgen grows revenue about 6% yearly, driven by innovation. Profit margins stay stable with EPS guidance near $16.36 for 2026. The company manages capital well, increasing debt strategically to fund growth. Recent court wins support key drug revenues.
Regulators threaten to revoke rights to a rare-disease drug, risking growth. Patent lawsuits and product withdrawals raise concerns about innovation. The recent selloff reflects these risks and soft guidance.
The price is about 21% above our fair value near $302, reflecting roughly 3% revenue growth. Our fair value is below the Street median, indicating some optimism in the market that we do not fully share.
Breaks if: Debt falls significantly below $54B without clear capital plan
Utilize debt issuance as a strategic tool for capital management.
Stated in 2 of last 2 quarters. Debt outstanding increased from $54.6B in 2025-Q4 to $57.3B in 2026-Q1, reflecting the strategic use of debt issuance for capital management. The trajectory aligns with management's stated capital allocation strategy.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Company issued $4B in senior notes for capital management.”
“Debt issuance used as a strategic tool for capital management.”
Breaks if: EPS falls below $15.62 in FY26
Breaks if: Marketing authorization revoked for key rare-disease drug
Focus on advancing innovative therapies to sustain long-term growth.
Stated in 6 of last 6 quarters. Revenue grew from $8.1B in 2025-Q1 to $8.6B in 2026-Q1. The trajectory shows delivering on growth through innovation, as evidenced by consistent revenue increases and product sales growth.
“CEO: 'Confident in our ability to deliver attractive long-term growth.'”
“CEO: 'Clear path towards advancing innovative therapies to deliver sustained long-term growth.'”
“CEO: 'Focused on expanding access, advancing innovation, and sustaining long-term growth.'”
“CEO: 'Invest in science that enables longer, healthier lives and supports sustainable, long-term growth.'”
“CEO: 'Confident in our long-term growth prospects.'”
“CEO: 'Investing heavily in our rapidly advancing pipeline to deliver innovative therapies.'”
Breaks if: Revenue falls below $36B in FY26
Focus on advancing innovative therapies to sustain long-term growth.
Stated in 6 of last 6 quarters. Revenue grew from $8.1B in 2025-Q1 to $8.6B in 2026-Q1. The trajectory shows delivering on growth through innovation, as evidenced by consistent revenue increases and product sales growth.
“CEO: 'Confident in our ability to deliver attractive long-term growth.'”
“CEO: 'Clear path towards advancing innovative therapies to deliver sustained long-term growth.'”
“CEO: 'Focused on expanding access, advancing innovation, and sustaining long-term growth.'”
“CEO: 'Invest in science that enables longer, healthier lives and supports sustainable, long-term growth.'”
“CEO: 'Confident in our long-term growth prospects.'”
“CEO: 'Investing heavily in our rapidly advancing pipeline to deliver innovative therapies.'”